The 340B Drug Pricing Program, which allows uninsured or low-income patients to buy prescription drugs at discounted prices, is under attack — primarily by pharmaceutical companies, which stand to increase profits if the program is curtailed.
Dr. Hagop Kantarjian, chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center and a Baker Institute health policy fellow, and Dr. Robert Chapman, medical director of the Josephine Ford Cancer Institute at the Henry Ford Health System, provide background and support for the program in the Baker Institute Blog.
